Review
Open access
Oct 2026
Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice
Targeted therapy has revolutionized the treatment of non-small cell lung cancer (NSCLC) patients harboring oncogenic alterations, and next-generation tyrosine kinase inhibitors (TKIs) significantly increase blood-brain barrier (BBB) penetration, leading to improved disease control and survival benefits. However, severa...
Chao-Zhuo Li, Xiao-Yan Yin, Shu-Qing Zhou et al.
· Signal Transduction and Targ... · 0 citations